Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors

Capmatinib is a highly specific, potent and selective MET inhibitor. This was an open‐label, multicenter, dose‐escalation, phase I study conducted in Japanese patients with advanced solid tumors (not selected based on their MET status). The primary objective was to determine the maximum tolerated dose (MTD) and/or highest studied dose being safe. Secondary objectives included safety, pharmacokinetics and preliminary antitumor activity. Dose escalation was guided by a Bayesian Logistic Regression Model dependent on dose‐limiting toxicities (DLT) in cycle 1. Of 44 adult Japanese patients with confirmed advanced solid tumors enrolled, 29 received capmatinib capsules (doses ranging from 100 mg once daily [q.d.] to 600 mg twice daily [b.i.d.]) and 15 received tablets (200 mg b.i.d. and 400 mg b.i.d.). DLT occurred in two patients: grade 2 suicidal ideation (600 mg b.i.d. capsule) and grade 3 depression (400 mg b.i.d. tablet). MTD was not reached. The highest studied dose determined to be safe as tablet was 400 mg b.i.d., whereas it is not yet determined for capsules. Most common adverse events suspected to be drug‐related were increased blood creatinine, nausea, decreased appetite, vomiting and diarrhea. Following repeated daily dosing up to day 15 by q.d. or b.i.d. regimen using capsules, median time to reach maximum plasma drug concentration (Tmax) was 1.0‐4.0 hours; absorption was more rapid after dosing using tablets, with median Tmax of 1.0 hour on both days 1 and 15. Eight patients had a best overall response of stable disease. These data support further clinical development of capmatinib.

[1]  P. Paik,et al.  Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial. , 2018 .

[2]  Jeffrey W. Clark,et al.  Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. , 2018 .

[3]  Y. Bang,et al.  Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC). , 2016 .

[4]  Jeffrey W. Clark,et al.  Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). , 2016 .

[5]  A. Warth,et al.  Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? , 2015, Diagnostic Pathology.

[6]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[7]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[8]  F. Cappuzzo,et al.  Onartuzumab in lung cancer: the fall of Icarus? , 2015, Expert review of anticancer therapy.

[9]  K. Nishio,et al.  Targeting MET Amplification as a New Oncogenic Driver , 2014, Cancers.

[10]  D. Nam,et al.  Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. , 2014 .

[11]  R. Salgia,et al.  MET as a possible target for non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Tsao,et al.  c-MET as a potential therapeutic target and biomarker in cancer , 2011, Therapeutic advances in medical oncology.

[13]  Qian Wang,et al.  A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3 , 2011, Clinical Cancer Research.

[14]  T. Mok,et al.  Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer , 2009, Pathology & Oncology Research.

[15]  A. Marchetti,et al.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Michael Branson,et al.  Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.

[17]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[18]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[19]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.

[20]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[21]  J. Laterra,et al.  Targeting the c-Met Pathway Potentiates Glioblastoma Responses to γ-Radiation , 2005, Clinical Cancer Research.

[22]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[23]  J. Laterra,et al.  Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  B. Teh,et al.  Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients , 2004, Clinical Cancer Research.

[25]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[26]  R. Salgia,et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.

[27]  P. Comoglio,et al.  Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. , 2002, Cancer research.

[28]  L. Schmidt,et al.  A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.

[29]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[30]  M. Tsao,et al.  Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. , 1998, Lung cancer.